» Articles » PMID: 32883904

Catch the Rainbow: Prognostic Factor of Sarcoidosis

Overview
Journal Lung India
Specialty Pulmonary Medicine
Date 2020 Sep 5
PMID 32883904
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Sarcoidosis is a systemic, chronic, inflammatory disease characterized by noncaseating granuloma formations. The fact that the etiopathogenesis of the disease has not been elucidated yet brings it many theories and assumptions. Being a systemic disease and ability to involve many organs and systems, it attracts the attention of physicians from different branches. In addition to lung involvement, skin, eye, heart, and locomotor system involvement is an important clinical finding. Sarcoidosis may present with very different clinical presentations, and therefore, it is one of the important "imitators" in the medical literature. I like sarcoidosis as a "rainbow," it is a disease that contains the characteristics of many diseases. Different clinical, radiological, and laboratory prognostic factors (lupus pernio, chronic uveitis, late-onset disease, chronic hypercalcemia, nephrocalcinosis, Afro-American race, progressive pulmonary sarcoidosis, radiologic Stage 4, bone involvement, neurosarcoidosis, cardiac involvement, and chronic respiratory failure) have been defined in this "rainbow." Early identification of these factors plays an important role in the determination of treatment strategies, morbidity, and mortality of the disease. In this article, clinical, genetic, laboratory, and radiological factors that determine the prognosis of sarcoidosis are discussed in light of the latest data in the literature.

Citing Articles

Clinical manifestations and associated factors of uveitis in patients with pulmonary sarcoidosis: a case control study.

Lee J, Han Y, Yang J, Kim H, Lee J Sci Rep. 2023; 13(1):22380.

PMID: 38104161 PMC: 10725472. DOI: 10.1038/s41598-023-49894-5.


Lymphocyte Subsets and Pulmonary Nodules to Predict the Progression of Sarcoidosis.

Danila E, Aleksoniene R, Besusparis J, Gruslys V, Jurgauskiene L, Laurinaviciene A Biomedicines. 2023; 11(5).

PMID: 37239108 PMC: 10216233. DOI: 10.3390/biomedicines11051437.


The Overlap of Kidney Failure in Extrapulmonary Sarcoidosis in Children-Case Report and Review of Literature.

Mocanu A, Bogos R, Trandafir L, Cojocaru E, Ioniuc I, Alecsa M Int J Mol Sci. 2023; 24(8).

PMID: 37108489 PMC: 10138650. DOI: 10.3390/ijms24087327.


Treat to target and tight control: Could be a new approach in the treatment of sarcoidosis?.

Kobak S Intractable Rare Dis Res. 2023; 12(1):22-28.

PMID: 36873668 PMC: 9976097. DOI: 10.5582/irdr.2022.01123.


Sarcoidosis and its oral manifestations: A case report study.

Shahabinejad M, Delavarian Z, Zamani T, Fallah Toosi F Clin Case Rep. 2023; 11(2):e6923.

PMID: 36789320 PMC: 9913189. DOI: 10.1002/ccr3.6923.


References
1.
MITCHELL D . Mycobacteria and sarcoidosis. Lancet. 1996; 348(9030):768-9. DOI: 10.1016/S0140-6736(05)65205-1. View

2.
Song Z, Marzilli L, Greenlee B, Chen E, Silver R, Askin F . Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005; 201(5):755-67. PMC: 2212832. DOI: 10.1084/jem.20040429. View

3.
Sweiss N, Lower E, Mirsaeidi M, Dudek S, Garcia J, Perkins D . Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014; 43(5):1525-8. PMC: 4167390. DOI: 10.1183/09031936.00224513. View

4.
Iannuzzi M, Rybicki B, Teirstein A . Sarcoidosis. N Engl J Med. 2007; 357(21):2153-65. DOI: 10.1056/NEJMra071714. View

5.
Selroos O, Gronhagen-Riska C . Angiotensin converting enzyme. III. Changes in serum level as an indicator of disease activity in untreated sarcoidosis. Scand J Respir Dis. 1979; 60(6):328-36. View